A deep-dive reference for pharmaceutical IP teams, R&D leads, payer strategy groups, and institutional investors. Executive Summary The question of […]
I. Why Patent Strategy Is Really Business Strategy Here is a number worth sitting with: the U.S. pharmaceutical industry spent
Drug Patents: The Complete Playbook for Pharmaceutical Competitive Advantage Read Post »
Executive Lead: Why Emerging Markets Are the Only Game That Matters The global generic drug market will reach approximately USD
Generic Drug Entry in Emerging Markets: The $927B Patent Cliff Playbook Read Post »
Global Pharmaceutical Distribution and Patent Exclusivity: A Strategic Framework The global pharmaceutical market exceeds 1.48 trillion dollars in annual valuation.
Executive Summary Dupixent (dupilumab) is one of the most commercially successful biologics in history, generating over $14.9 billion in global
Merck made $29.5 billion from a single drug last year. That drug, Keytruda, loses its primary patent in 2028. Read
The $236 Billion Cliff: How Pharma Loses Its Blockbusters—and What Replaces Them Read Post »
The Molecular Reality: Why Biosimilars Cannot Be Generics The entire strategic, regulatory, and commercial architecture around biosimilars flows from one
A deep-dive reference for pharma IP teams, R&D leads, and institutional investors on the science, strategy, and commercial mechanics of
Sign in or create a free account to read this DrugPatentWatch article
